Assessment of tumour-agnostic therapies in basket trials

Lancet Oncol. 2022 Jan;23(1):e7. doi: 10.1016/S1470-2045(21)00714-2.

Authors

Sanjay Popat¹, Sreeram V Ramagopalan², Joshua Ray², Stéphane Roze³, Vivek Subbiah⁴

Affiliations

¹ Lung Unit, Royal Marsden National Health Service Foundation Trust, Chelsea, London, UK.
² Global Access, F. Hoffmann-La Roche, Basel, Switzerland.
³ Vyoo Agency, Villeurbanne, France.
⁴ Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: vsubbiah@mdanderson.org.

PMID: 34973234
DOI: 10.1016/S1470-2045(21)00714-2

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Molecular Targeted Therapy
Neoplasms* / drug therapy